#AAD26 roundup: Takeda, Alumis, Priovant and Incyte take the stagenews2026-03-30T18:22:30+00:00March 30th, 2026|Endpoints News|
Drugmakers skeptical of new White House overtures on pricingnews2026-03-30T17:58:06+00:00March 30th, 2026|Endpoints News|
Samsung Bio union workers threaten strike over pay, disclosure of employee datanews2026-03-30T17:44:16+00:00March 30th, 2026|Endpoints News|
Post-Hoc Live: Will MAHA vaccine policies be a political problem for Republicans?news2026-03-30T17:43:34+00:00March 30th, 2026|Endpoints News|
Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?news2026-03-30T15:28:50+00:00March 30th, 2026|Endpoints News|
Blackstone raises $6.3B life sciences fund in record fundraising haulnews2026-03-30T15:12:18+00:00March 30th, 2026|Endpoints News|
Takeda cuts 600+ US jobs; United’s stock rises on Tyvaso datanews2026-03-30T15:01:45+00:00March 30th, 2026|Endpoints News|
#ACC26: Kardigan’s repeat dosing of blood pressure drug has no benefit over single shotnews2026-03-30T14:22:03+00:00March 30th, 2026|Endpoints News|
Eli Lilly to pay $115M upfront to Insilico in AI drug discovery dealnews2026-03-30T14:07:39+00:00March 30th, 2026|Endpoints News|
#ACC26: Braveheart Bio’s Hengrui-originated pill posts China data in heart muscle diseasenews2026-03-30T13:30:46+00:00March 30th, 2026|Endpoints News|
